No Data
No Data
Jonathan Wolleben's Positive Outlook on Structure Therapeutics, Inc. Driven by Unique Small Molecule Amylin Agonist and Promising Obesity Pipeline
We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate
Allurion Stock Soars 70% on Weight-loss Therapy Update
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Stifel Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $50
Stifel Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $50